State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada
Zip Code
Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe
FILIPINO political analyst and author Adolfo Paglinawan said the United States' alleged disinformation drive to undermine China's Sinovac drug at the height of the Covid-19 pandemic highlighted the use of disinformation as a geopolitical weapon.
News agency Reuters recently released a report on the US black propaganda against Chinese vaccines.
Staff members unload the 2nd batch of the Sinovac vaccine donated by China at the Ninoy Aquino International Airport Terminal 2 in Manila, the Philippines on March 24, 2021. (Xinhua/Rouelle Umali)
Some commentators in the Philippines pointed out that if the United States launched such a secret disinformation campaign to discredit Chinese vaccines during the COVID-19 pandemic, it could well be running another round to portray China as a "bully" in the South China Sea.
MANILA, June 20 (Xinhua) -- People around the world are "indignant" about the reported U.S. military's secret psychological warfare of discrediting Chinese vaccines, a spokesperson of the Chinese Embassy in the Philippines has said in a statement.
The U.S. military's actions lay bare the hypocrisy, malign intention and double standards of the United States, according to the statement released on Tuesday.
China, as a responsible major country, provided global public goods such as vaccines to other countries during the COVID-19 pandemic, the statement said.
China was the first to provide COVID-19 response supplies and vaccines to the Philippines, it said, adding that China and the Philippines have been mutually supportive and cooperative against the onslaught of the disease, making important contributions to the world's final victory over the pandemic.
However, the cooperation was not as smooth as it was supposed to be due to obstruction and sabotage by a third country and certain forces, the statement said.
"Of course, such a plot doomed to failure as it went against the interests of the Chinese and Filipino peoples," it said.
While talking about respecting human rights frequently, the United States does just the opposite regarding the fundamental human rights of life and health of the Filipino people, the statement said.
While reaffirming its so-called ironclad commitment to its allies all the time, when it comes to the critical moment of fighting the pandemic together, the United States always pursued the policy of America First, exploiting the vulnerability of the Filipino people for its ulterior geopolitical motives, it said.
"By denying access to Chinese assistance, and in defiance of the global public opinion, the United States dares to spread rumors and spin stories on major global public health issues including the vaccine," it said.
"We hope that the United States will behave the way it claims to be, and stop fabricating and spreading disinformation against other countries. It is expected to shoulder responsibility of a major country, truly respect the effort of other countries in safeguarding people's health, well-being and peace and stability of the region," the statement said.
Some commentators in the Philippines pointed out that if the United States launched such a secret disinformation campaign to discredit Chinese vaccines during the COVID-19 pandemic, it could well be running another round to portray China as a "bully" in the South China Sea.
In response to such remarks, the Chinese embassy in the Philippines said that the Chinese and Filipino people "should remain highly vigilant and clear-eyed, resist being taken in by disinformation and inflammatory rhetoric, define their own fate and protect China-Philippines relations as well as peace and stability in the South China Sea."
Breadcrumb Trail Links
The union representing Cargill employees at its High River plant was seeking about $20 million in damages
Published Jun 19, 2024 Last updated 23hours ago 4 minute read
You can save this article by registering for free here. Or sign-in if you have an account.
Cargill wont have to pay about $20 million in damages for how it handled the first months of the COVID-19 pandemic and subsequent outbreak which claimed the lives of two employees and one workers father.
The decision ends a four-year-long battle between the major meat producer and its employees union, which came in the wake of the three deaths and 951 COVID-19 cases connected to the meat-processing plants workforce the largest single outbreak recorded during the pandemic.
Advertisement 2
This advertisement has not loaded yet, but your article continues below.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
or
Article content
The three deaths linked to the outbreak were Hiep Bui, a 67-year-old shop steward; Benito Quesada, a 51-year-old shop steward; and Armando Sallegue, the 71-year-old father of a Cargill employee.
In his June 10 decision, Arbitrator James Casey wrote that the limited and rapidly changing information around the virus during the first months of the pandemic was a factor that weighed heavily on his conclusion Cargill largely met its obligations to ensure the health and safety of its High River employees.
When the pandemic broke, public health authorities determined food processing plants such as Cargills slaughterhouse were critical services and werent required to close. (At the time, Cargills High River plant provided about 30 per cent of Canadas beef and 40 per cent of Albertas supply.)
Recommended from Editorial
'Disturbing' review shows Cargill failed to engage workers during COVID-19 investigation
Cargill criminal investigation a Canadian first, but case could be difficult to prosecute: experts
RCMP investigating Cargill worker's death from COVID-19
But the logistics of safely running a meat-packing plant were challenging: A centre like Cargills requires large numbers of employees working close together on an open production line, making it a high-risk transmission area. On the advice of public health bodies, Casey wrote, Cargill had instituted by late February 2020 a series of safety measures to protect workers against droplet transmission and physical contact the two prevailing ways the scientific community believed COVID-19 was transmitted at the time.
Noon News Roundup
Your weekday lunchtime roundup of curated links, news highlights, analysis and features.
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Thanks for signing up!
A welcome email is on its way. If you don't see it, please check your junk folder.
The next issue of Noon News Roundup will soon be in your inbox.
We encountered an issue signing you up. Please try again
Article content
Advertisement 3
This advertisement has not loaded yet, but your article continues below.
Article content
That approach did not take into account the then-unknown reality COVID-19 could spread through airborne or aerosol transmission, which was established much later in the pandemic, Casey wrote. In April 2020, he noted, Alberta Health Services (AHS) wrote in its Frequently Asked Questions page that COVID-19 was not an airborne illness.
Employers, unions, governments and public health authorities had to make it up as they went along, he wrote.
The plants first case was confirmed on April 6, prompting the United Food and Commercial Workers (UFCW) Local No. 401 representing Cargill employees to call for a temporary two-week closure. Across North America, 30 UFCW employees had already died. At the same time, members of High Rivers Filipino community wrote to the mayor imploring him to convince Cargill to close the plant.
The fear in the community was intense, Casey wrote. Soon after, swaths of employees stopped coming to work while AHS set up a Cargill Task Force to try to control the outbreak, though the public health body believed the risk of transmission at the plant was relatively low. AHS greater concern, Casey wrote, was transmission from employees living together and carpooling.
Advertisement 4
This advertisement has not loaded yet, but your article continues below.
Article content
On April 22, 2020, two days after the first employee was killed by the virus, Cargill temporarily closed the plant due to low attendance. Two days later, UFCW filed the grievance, claiming Cargill wasnt meeting its obligation to provide a safe work environment.
The plant reopened in early May. On May 12, the union announced the death of a second employee. Little more than a month later on June 19, 2020, AHS determined the Cargill outbreak had resulted in 902 COVID-19 cases the largest in Canada in the first year of the pandemic. More than 1,500 cases were eventually linked to the outbreak, with 951 employees testing positive about half the plants entire workforce.
In its grievance filing for that two-month period, UFCW demanded Cargill pay each employee $10,000 and pay the union $100,000. Because there were about 2,000 employees in the bargaining unit, the union was seeking about $20 million in damages.
The eventual 19-day arbitration saw the union call eight witnesses and Cargill bring six witnesses. It is fair to say, that the parties have left no stone unturned in the intense examination of Cargills actions, Casey wrote.
Advertisement 5
This advertisement has not loaded yet, but your article continues below.
Article content
The central issues in the arbitration were the state of public health knowledge at the time, and whether Cargills safety measures were effective given the mode of virus transmission.
Casey eventually concluded that Cargill followed advice of public health authorities which was in line with what was known at the time about COVID-19. While the union argued this advice was mistaken and therefore didnt protect employees, Casey wrote that Cargill and health authorities were relying on limited information at the time.
It is not appropriate to second-guess Cargills decision based on current scientific knowledge about COVID-19 and current regulatory advice, he wrote.
Casey noted that Cargill did fail to comply with its obligations to communicate with the Joint Health and Safety Committee to identify hazards and address those hazards, which is a direct contravention of the Occupational Health and Safety Act. While he said awarding damages for this breach wouldnt be appropriate, he added the company failed to comply with its collective agreement in a narrow but important way.
He dismissed the remaining grievances.
Cargill and UFCW Local 401 did not immediately respond to Postmedias request for comment.
Alberta RCMP announced in January 2021 that it was investigating Quesadas death. Mounties confirmed to Postmedia on Wednesday that the file was closed and Quesadas death was deemed non-criminal.
mscace@postmedia.com X: @mattscace67
Article content
Share this article in your social network
A team of scientists has identified previously unrecognized immune responses that explain why some individuals do not contract COVID-19.
The experts utilized single-cell sequencing to investigate immune reactions to SARS-CoV-2 in healthy volunteers as part of the worlds first COVID-19 human challenge study.
The research was led by researchers from Wellcome Sanger Institute, University College London (UCL), Imperial College London, and the Netherlands Cancer Institute.
The study involved 36 volunteers exposed to the virus, with detailed monitoring revealing unique immune responses associated with resisting infection.
This was an incredibly unique opportunity to see what immune responses look like when encountering a new pathogen in adults with no prior history of COVID-19, in a setting where factors such as time of infection and comorbidities could be controlled, said co-first author Rik Lindeboom, a researcher at the Netherlands Cancer Institute.
These findings shed new light on the crucial early events that either allow the virus to take hold or rapidly clear it before symptoms develop, noted study senior author Marko Nikoli, a clinical scientist fellow at UCL.
We now have a much greater understanding of the full range of immune responses, which could provide a basis for developing potential treatments and vaccines that mimic these natural protective responses.
Using single-cell sequencing, the researchers generated a dataset of over 600,000 cells. They discovered immediate virus detection responses, including activation of specialized mucosal immune cells and a reduction in inflammatory white blood cells.
Individuals who cleared the virus immediately showed unique innate immune responses, influenced by high pre-exposure activity of the gene HLA-DQA2. Those who developed sustained infections had a rapid blood immune response but a slower nasal response.
As were building the Human Cell Atlas we can better identify which of our cells are critical for fighting infections and understand why different people respond to coronavirus in varied ways, said Sarah Teichmann, co-founder of the Human Cell Atlas.
Future studies can compare with our reference dataset to understand how a normal immune response to a new pathogen compares to a vaccine-induced immune response.
The study also identified patterns in T cell receptors, offering insights for targeted T cell therapies.
Shobana Balasingam from Wellcome emphasized the value of human challenge models in understanding the bodys response to infectious diseases, highlighting the need for such studies in low-resource settings to develop effective tools and treatments.
This research provides critical insights into immune mechanisms that allow some individuals to avoid COVID-19, offering potential pathways for improved therapeutic strategies and vaccine designs.
By understanding these natural protective responses, scientists can better inform the development of treatments and preventive measures for COVID-19 and other infectious diseases.
COVID-19, caused by the SARS-CoV-2 virus, invades the body through a multi-step process.
Initially, the virus enters the body primarily through the respiratory system, as people inhale droplets containing the virus from an infected persons coughs, sneezes, or speech. The virus can also enter through the eyes, nose, and mouth.
Once inside, the virus targets specific cells in the respiratory tract by using its spike protein to bind to ACE2 receptors on the surface of these cells, which are abundant in areas such as the lungs, heart, kidneys, and intestines.
Upon binding to the ACE2 receptor, the viruss membrane fuses with the host cell membrane, allowing the viral RNA to penetrate the host cell.
Inside the host cell, the viral RNA takes control of the cells machinery, directing it to replicate the viral RNA and produce viral proteins necessary for creating new virus particles. These new viral particles are then assembled within the host cell.
Once assembled, the new viral particles are released from the host cell and proceed to infect neighboring cells, thereby spreading the infection throughout the body.
The bodys immune system responds to this invasion, often leading to inflammation and symptoms associated with COVID-19, such as fever, cough, and difficulty breathing.
In severe cases, this can result in complications like pneumonia, acute respiratory distress syndrome (ARDS), and multi-organ failure, as the immune systems response can cause significant tissue damage.
The study is published in the journal Nature.
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates.
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.
Rare types of cancer are showing up in higher numbers since the Covid-19 pandemic. Doctors suspect that the virus itself may be contributing to the higher cancer rates, despite a solid connection not yet being established. The pandemic may have permanently altered the bodies of those infected, making them more susceptible to cancer. Those affected include people who were otherwise previously healthy.
Doctors have identified a marked increase in late-stage rarer cancers in people who had otherwise been healthy. Lung, blood and colon cancer, especially, have been rising in younger people. Specifically, medical experts have observed a rise in new cancer patients, multiple patients with multiple cancers, couples and siblings developing cancer within months of each other and cancer patients relapsing after years of remission.
The trend has been particularly noticeable since the Covid-19 pandemic. "This is an observation that has piqued the researchers' and clinicians' interest, that, is there an association with Covid, especially long Covid and cancer?" Dr. Suraj Saggar, chief of infectious disease at Holy Name Hospital in Teaneck, New Jersey, said to Fox 5 New York.
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
SUBSCRIBE & SAVE
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Cancer is caused by errors in genetic code within cells. "The human body is made up of trillions of cells in a constant state of growth, repair and death," said The Washington Post. "Most of the time, cells with damaged DNA fix themselves, or simply disappear. Sometimes, they start collecting mistakes in their genetic code and rampage out of control into tumors."
What is more alarming is the prevalence of people suffering from more than one type of cancer. "Having multiple forms of cancer at the same time has also become more prevalent. Cancers typically start in one part of the body and spread," the Post said. "It's rare for discrete cancers to begin in different parts of the body during a short window."
Some scientists posit that the Covid virus itself could be contributing to the higher numbers of cancer diagnoses, especially for those who are suffering from long Covid. "The idea that some viruses can cause or accelerate cancer is hardly new," said the Post. "Scientists have recognized this possibility since the 1960s, and today, researchers estimate 15% to 20% of all cancers worldwide originate from infectious agents such as HPV, Epstein-Barr and hepatitis B."
Because "infection with SARS-CoV-2 occurs in several organs either directly or indirectly, it is expected that cancer stem cells may develop in multiple organs," said a 2023 study published in the journal Biochimie. Lung, colorectal, pancreatic and oral cancer could particularly be exacerbated.
While not officially confirmed, the virus is said to cause full-body inflammation. "Inflammation triggers many genetic changes in a genome that can create a propensity of developing cancer in certain individuals," Dr. Kashyap Patel, CEO of Carolina Blood and Cancer Care Associates, said to News Nation. "We are completely under-investigating this virus," Douglas C. Wallace, a geneticist and evolutionary biologist at the University of Pennsylvania, said to the Post. "The effects of repeatedly getting this throughout our lives is going to be much more significant than people are thinking."
To continue reading this article...
Create a free account
Continue reading this article and get limited website access each month.
Already have an account? Sign in
Subscribe to The Week
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Unlimited website access is included with Digital and Print + Digital subscriptions. Create an account with the same email registered to your subscription to unlock access.
Yesterday in Nature Communications a study shows cancer that patients who are up to date on vaccines and have received COVID-19 boosters are more protected against death and serious complications than unvaccinated patients.
Cancer patients were not included in key randomized clinical trials on vaccine efficacy (VE), the authors of the study write, but they are at increased risk of death and serious illness from COVID-19 infections. Those especially at risk include lung cancer patients, those with hematologic cancer, and those undergoing chemotherapy.
The authors said prospective data on immunogenicity following initial vaccination have shown that cancer patients develop protective antibodies against SARS-CoV-2 but in lower rates than the general population.
In the study, Spanish researchers looked at data from clinical registries on 184,744 cancer patients in Catalonia, Spain. Half of the patients (92,372) had received at least the first complete immunization series, and the other half (92,372) had not been vaccinated at the time of the study.
All participants had received a cancer diagnosis from 2015 to 2020. The most common cancers included were breast, prostate, and colorectal.
The proportion who received one, two, and three (booster) doses of COVID-19 vaccines were 87.2%, 84.9%, and 68.2%, respectively, the authors said.
The researchers found that cancer patients had 51.8% (95% confidence interval [CI], 40.3% to 61.1%) and 58.4% (95% CI, 29.3% to 75.5%) protection against COVID-19 hospitalization and COVID-19 death, respectively after full (two-dose) vaccination and 77.9% (95% CI, 69.2% to 84.2%) and 80.2% (95% CI, 63.0% to 89.4%) after a booster dose.
Protection from booster doses was high, hovering around 75%, the authors said, but waned significantly by 120 days post-injection.
"Patients should be encouraged to get vaccinated if not and boosted if they have had only two doses," the authors concluded. "Because of the higher risk of breakthrough infections, hospitalizations, and death compared to healthy individuals, patients with cancer should be prioritized in future additional dose studies and vaccination campaigns."
Patients should be encouraged to get vaccinated if not and boosted if they have had only two doses.
In an ISGlobal press release on the study, co-senior author Otavio Ranzani, MD, PhD, said the results "clearly demonstrate that vaccination against COVID-19 significantly reduces mortality and serious complications among cancer patients, especially those who have received the booster dose."
Atkinson, M. A., Eisenbarth, G. S. & Michels, A. W. Type 1 diabetes. Lancet 383, 6982 (2014).
Article PubMed Google Scholar
Roep, B. O. The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia 46, 305321 (2003).
Article CAS PubMed Google Scholar
Pociot, F. & Lernmark, . Genetic risk factors for type 1 diabetes. Lancet 387, 23312339 (2016).
Article CAS PubMed Google Scholar
Moltchanova, E. V., Schreier, N., Lammi, N. & Karvonen, M. Seasonal variation of diagnosis of type 1 diabetes mellitus in children worldwide. Diabet. Med. 26, 673678 (2009).
Article CAS PubMed Google Scholar
Patterson, C. et al. Seasonal variation in month of diagnosis in children with type 1 diabetes registered in 23 European centers during 19892008: little short-term influence of sunshine hours or average temperature. Pediatr. Diabetes 16, 573580 (2015).
Article CAS PubMed Google Scholar
Sderstrm, U., Aman, J. & Hjern, A. Being born in Sweden increases the risk for type 1 diabetes a study of migration of children to Sweden as a natural experiment. Acta Paediatr. 101, 7377 (2012).
Article PubMed Google Scholar
Wang, Z., Xie, Z., Lu, Q., Chang, C. & Zhou, Z. Beyond genetics: what causes type 1 diabetes. Clin. Rev. Allerg. Immunol. 52, 273286 (2017).
Article CAS Google Scholar
Olmos, P. et al. The significance of the concordance rate for type 1 (insulin-dependent) diabetes in identical twins. Diabetologia 31, 747750 (1988).
Article CAS PubMed Google Scholar
Peng, H. & Hagopian, W. Environmental factors in the development of type 1 diabetes. Rev. Endocr. Metab. Disord. 7, 149162 (2007).
Article Google Scholar
Patelarou, E. et al. Current evidence on the associations of breastfeeding, infant formula, and cows milk introduction with type 1 diabetes mellitus: a systematic review. Nutr. Rev. 70, 509519 (2012).
Article PubMed Google Scholar
Stene, L. C. & Gale, E. A. M. The prenatal environment and type 1 diabetes. Diabetologia 56, 18881897 (2013).
Article CAS PubMed Google Scholar
van der Werf, N., Kroese, F. G. M., Rozing, J. & Hillebrands, J.-L. Viral infections as potential triggers of type 1 diabetes. Diabetes Metab. Res. Rev. 23, 169183 (2007).
Article PubMed Google Scholar
Nekoua, M. P., Alidjinou, E. K. & Hober, D. Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nat. Rev. Endocrinol. 18, 503516 (2022). This Review highlights evidence that persistent Coxsackievirus B infection triggers or accelerates islet autoimmunity and T1DM in susceptible individuals.
Article CAS PubMed PubMed Central Google Scholar
Soltesz, G., Patterson, C. & Dahlquist, G.; EURODIAB Study Group. Worldwide childhood type 1 diabetes incidence what can we learn from epidemiology? Pediatr. Diabetes 8, 614 (2007).
Article PubMed Google Scholar
Hober, D. & Sauter, P. Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host. Nat. Rev. Endocrinol. 6, 279289 (2010). The interplay between enterovirus infection with -cells, the immune system and host genes in the pathogenesis of T1DM is discussed.
Article PubMed Google Scholar
Lnnrot, M. et al. Respiratory infections are temporally associated with initiation of type 1 diabetes autoimmunity: the TEDDY study. Diabetologia 60, 19311940 (2017). A prospective study of 8,676 newborn babies reporting that viral respiratory infections are associated with an increased risk of islet autoimmunity.
Article PubMed PubMed Central Google Scholar
Rasmussen, T., Wits, E., Tapia, G., Stene, L. C. & Rnningen, K. S. Self-reported lower respiratory tract infections and development of islet autoimmunity in children with the type 1 diabetes high-risk HLA genotype: the MIDIA study. Diabetes Metab. Res. Rev. 27, 834837 (2011).
Article CAS PubMed Google Scholar
Beyerlein, A., Wehweck, F., Ziegler, A.-G. & Pflueger, M. Respiratory infections in early life and the development of islet autoimmunity in children at increased type 1 diabetes risk: evidence from the BABYDIET study. JAMA Pediatr. 167, 800807 (2013).
Article PubMed Google Scholar
Mustonen, N. et al. Early childhood infections precede development of beta-cell autoimmunity and type 1 diabetes in children with HLA-conferred disease risk. Pediatr. Diabetes 19, 293299 (2018).
Article CAS PubMed Google Scholar
Lee, H.-Y., Lu, C.-L., Chen, H.-F., Su, H.-F. & Li, C.-Y. Perinatal and childhood risk factors for early-onset type 1 diabetes: a population-based case-control study in Taiwan. Eur. J. Public Health 25, 10241029 (2015).
Article PubMed Google Scholar
Ruiz, P. L. D. et al. Pandemic influenza and subsequent risk of type 1 diabetes: a nationwide cohort study. Diabetologia 61, 19962004 (2018).
Article PubMed PubMed Central Google Scholar
Kordonouri, O. et al. Infections in the first year of life and development of beta cell autoimmunity and clinical type 1 diabetes in high-risk individuals: the TRIGR cohort. Diabetologia 65, 20982107 (2022).
Article CAS PubMed PubMed Central Google Scholar
Beyerlein, A., Donnachie, E., Jergens, S. & Ziegler, A.-G. Infections in early life and development of type 1 diabetes. JAMA 315, 18991901 (2016).
Article PubMed Google Scholar
Wu, R. et al. Respiratory infections and type 1 diabetes: potential roles in pathogenesis. Rev. Med. Virol. 33, e2429 (2023).
Article CAS PubMed PubMed Central Google Scholar
Ho, D. et al. Identifying the lungs as a susceptible site for allele-specific regulatory changes associated with type 1 diabetes risk. Commun. Biol. 4, 1072 (2021).
Article CAS PubMed PubMed Central Google Scholar
Kim, D. et al. The architecture of SARS-CoV-2 transcriptome. Cell 181, 914921 (2020).
Article CAS PubMed PubMed Central Google Scholar
Liu, Y.-C., Kuo, R.-L. & Shih, S.-R. COVID-19: the first documented coronavirus pandemic in history. Biomed. J. 43, 328333 (2020).
Article PubMed PubMed Central Google Scholar
Liu, J. et al. SARS-CoV-2 cell tropism and multiorgan infection. Cell Discov. 7, 17 (2021).
Article CAS PubMed PubMed Central Google Scholar
Unsworth, R. et al. New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care 43, e170e171 (2020).
Article CAS PubMed Google Scholar
Kamrath, C. et al. Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: results from the DPV registry. Diabetes Care 45, 17621771 (2022).
Article CAS PubMed Google Scholar
Gesuita, R. et al. Trends and cyclic variation in the incidence of childhood type 1 diabetes in two Italian regions over 33 years and during the COVID-19 pandemic. Diabetes Obes. Metab. 25, 16981703 (2023).
Article CAS PubMed Google Scholar
Rabbone, I. et al. Has COVID-19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? Diabetes Care 43, 28702872 (2020).
Article CAS PubMed Google Scholar
Rahmati, M. et al. The global impact of COVID19 pandemic on the incidence of pediatric newonset type 1 diabetes and ketoacidosis: a systematic review and metaanalysis. J. Med. Virol. 94, 51125127 (2022).
Article CAS PubMed PubMed Central Google Scholar
DSouza, D. et al. Incidence of diabetes in children and adolescents during the COVID-19 pandemic: a systematic review and meta-analysis. JAMA Netw. Open 6, e2321281 (2023).
Article PubMed PubMed Central Google Scholar
Ruiz, P. L. D. et al. SARS-CoV-2 infection and subsequent risk of type 1 diabetes in 1.2 million children [abstract 233]. EASD 2022. https://www.easd.org/media-centre/home.html#!resources/sars-cov-2-infection-and-subsequent-risk-of-type-1-diabetes-in-1-2-million-children-3e68c8b2-dde1-43aa-8d75-af7356502994 (2022).
Kendall, E. K., Olaker, V. R., Kaelber, D. C., Xu, R. & Davis, P. B. Association of SARS-CoV-2 infection with new-onset type 1 diabetes among pediatric patients from 2020 to 2021. JAMA Netw. Open 5, e2233014 (2022).
Article PubMed PubMed Central Google Scholar
Qeadan, F. et al. The associations between COVID-19 diagnosis, type 1 diabetes, and the risk of diabetic ketoacidosis: a nationwide cohort from the US using the Cerner Real-World Data. PLoS One 17, e0266809 (2022).
Article CAS PubMed PubMed Central Google Scholar
Lugar, M. et al. SARS-CoV-2 infection and development of islet autoimmunity in early childhood. JAMA 330, 11511160 (2023).
Article CAS PubMed PubMed Central Google Scholar
McKeigue, P. M. et al. Relation of incident type 1 diabetes to recent COVID-19 infection: cohort study using e-health record linkage in Scotland. Diabetes Care 46, 921928 (2023).
Article PubMed Google Scholar
Noorzae, R., Junker, T. G., Hviid, A. P., Wohlfahrt, J. & Olsen, S. F. Risk of type 1 diabetes in children is not increased after SARS-CoV-2 infection: a nationwide prospective study in Denmark. Diabetes Care 46, 12611264 (2023).
Article PubMed Google Scholar
Messaaoui, A., Hajselova, L. & Tenoutasse, S. Anti-SARS-CoV-2 antibodies in new-onset type 1 diabetes in children during pandemic in Belgium. J. Pediatr. Endocrinol. Metab. 34, 13191322 (2021).
Article CAS PubMed Google Scholar
Jia, X. et al. Prevalence of SARS-CoV-2 antibodies in children and adults with type 1 diabetes. Diabetes Technol. Ther. 23, 517521 (2021).
Article CAS PubMed PubMed Central Google Scholar
Rewers, M. et al. SARS-CoV-2 infections and presymptomatic type 1 diabetes autoimmunity in children and adolescents from Colorado, USA, and Bavaria, Germany. JAMA 328, 12521255 (2022).
Article CAS PubMed PubMed Central Google Scholar
Krischer, J. P. et al. SARS-CoV-2 no increased islet autoimmunity or type 1 diabetes in teens. N. Engl. J. Med. 389, 474475 (2023).
Article CAS PubMed PubMed Central Google Scholar
Pietropaolo, M., Hotez, P. & Giannoukakis, N. Incidence of an insulin-requiring hyperglycemic syndrome in SARS-CoV-2-infected young individuals: is it type 1 diabetes? Diabetes 71, 26562663 (2022).
Article CAS PubMed PubMed Central Google Scholar
Rahmati, M. et al. New-onset type 1 diabetes in children and adolescents as postacute sequelae of SARS-CoV-2 infection: a systematic review and meta-analysis of cohort studies. J. Med. Virol. 95, e28833 (2023).
Article CAS PubMed Google Scholar
Kamrath, C., Eckert, A. J., Holl, R. W. & Rosenbauer, J. Impact of the COVID-19 pandemic on children and adolescents with new-onset type 1 diabetes. Pediatr. Diabetes 2023, e7660985 (2023). This meta-analysis, including 40 studies carried out worldwide, reports an increased incidence of T1DM during the COVID-19 pandemic as well as an increased risk of T1DM following SARS-CoV-2 infection.
Article Google Scholar
Zhang, T. et al. Risk for newly diagnosed diabetes after COVID-19: a systematic review and meta-analysis. BMC Med. 20, 444 (2022).
Article CAS PubMed PubMed Central Google Scholar
Lai, H. et al. Risk of incident diabetes after COVID-19 infection: a systematic review and meta-analysis. Metabolism 137, 155330 (2022).
Article CAS PubMed PubMed Central Google Scholar
Rubino, F. et al. New-onset diabetes in covid-19. N. Engl. J. Med. 383, 789790 (2020).
Article PubMed Google Scholar
Eslami, N. et al. SARS-CoV-2: receptor and co-receptor tropism probability. Curr. Microbiol. 79, 133 (2022).
This study aimed to investigate the expression of microRNAs in leukaemia patients and their association with CD markers. Our results showed significant differences in the expression of microRNAs between AML patients and individuals in the control group. A strong correlation between microRNAs was observed, indicating that the presence of one microRNA led to increased expression of other microRNAs. Additionally, we found that MicroRNA16, MicroRNA21, and MicroRNA221 expression levels exhibited significant differences between AML patients with a history of COVID-19 infection and individuals without an infection history. Moreover, significant fold changes were observed between microRNA expression levels, and the CD markers among AML patients were positive for COVID-19. Finally, the upregulation of MicroRNA137 in AML patients was identified as a novel diagnostic biomarker that may aid in diagnosing, prognosis, and assessing treatment response for AML patients.
The diagnosis and classification of AML require a meticulous approach, as the World Health Organization (WHO) advised, encompassing a comprehensive blend of clinical history, morphological evaluation, cytogenetic/molecular genetic analysis, and immunophenotyping. Nonetheless, the absence of cytogenetic/molecular analyses in numerous healthcare facilities underscores the utility of cytomorphological evaluation supplemented by immunophenotyping, which proves adequate for expedited diagnosis and classification of AML (de Morais et al., 2022).
MicroRNAs are often deregulated in the cancerous process of body cells, and some of them enhance tumorigenesis and cancer progression by increasing tumour growth, angiogenesis, invasion, and immune evasion. The expression level of microRNAs in cancer can be used to predict patient prognosis and clinical response to treatment26,27. Since most of the microRNAs are intracellular, circulating microRNAs have been found in different body fluids and are identified as new cancer biomarkers. This study showed that the expression of microRNAs in AML patients increased significantly, and their role in the prognosis of AML disease was well established, similar to other studies28,29.
AML patients often have standard karyotypes30. They are a heterogeneous group from the molecular point of view, and these molecular differences are related to the prognosis of the disease. Therefore, it is crucial to identify new molecular markers and validate their promising future in treating the disease31. One of these essential markers is FLT3. It has been determined that it can be introduced as a valuable marker for diagnosing AML. In this study, we showed that the frequency of FLT3 mutation in AML patients was higher than in the control group and functions as an essential marker in the diagnosis and prognosis of AML disease; these results are consistent with the previous studies32,33,34,35. Fluorescence in situ hybridisation (FISH) diagnosis was used to detect chromosomal abnormalities in patients with AML, and based on the results of this study, FISH was able to show chromosomal abnormalities and disorders in patients with sufficient accuracy. Previous studies have investigated that the diagnostic strategies of FISH in diagnosing AML can be used as an efficient and powerful tool compared with other methods36. Additionally, FISH can be used as one of the standard methods for detecting microRNA expression, which was utilised in this study and effectively demonstrated the expression of microRNAs. Other studies have also shown the reliability of FISH as a method for detecting microRNA expression levels, which is consistent with the present studys findings. This technique has consistently proven its effectiveness in accurately assessing and quantifying the expression of microRNAs, confirming the results obtained in this research37,38.
Recent investigations have unveiled a variety of microRNAs that are dysregulated in AML and play roles in disease pathogenesis. Among these miRNAs are hsa-miR-16, hsa-miR-497, and hsa-miR-125, which have been implicated in regulating NRAS gene expression and cellular processes relevant to cancer development and progression (Hussen et al., 2021, Kipkeeva et al., 2022).
The BCR gene is a key player in the pathogenesis of several cancers, including AML. It encodes a protein regulating cell growth, differentiation, and survival. Dysregulation of the BCR gene, often through chromosomal translocations, can lead to the formation of oncogenic fusion proteins that drive leukemogenesis (Boucher et al., 2023). In the context of AML, aberrant expression of microRNAs has been implicated in disease progression. Specifically, miRNAs such as hsa-miR-16, hsa-miR-497, and hsa-miR-125 have been identified as potential regulators of gene expression and cellular processes relevant to cancer development. These miRNAs may target the BCR gene, influencing its expression levels and activity. Dysregulation of hsa-miR-16, hsa-miR-497, and hsa-miR-125 could thus contribute to aberrant BCR signaling and AML pathogenesis (Szczepanek, 2020). Understanding the regulatory interactions between genes and these miRNAs in AML patients is crucial for elucidating the molecular mechanisms underlying the disease and identifying potential therapeutic targets. Targeting the dysregulated expression of these miRNAs or modulating gene activity may represent promising strategies for AML treatment. Further investigation into the functional roles of hsa-miRNAs in gene regulation and AML pathogenesis is needed to validate their potential as therapeutic targets or diagnostic biomarkers.
Here, for the first time, we identified that the changes in the association between some of the microRNAs and CD1a, CD2, and CD11b were the most apparent alterations among AML patients after infection with COVID-19. Some of these findings are aligned with and confirmed by the previous study of a systematic screening of genetic events in AML patients, which shows that the expression of CD markers CD1a, CD2, and CD11b in AML patients is significantly increased39. The present study is also consistent with the analysis of Li et al.40, which shows increased expression of CD markers CD1a, CD2, and CD11b in Mixed-phenotype acute leukaemia (MPAL) patients, and they have revealed that these three CD markers are among the CD markers that have the highest expression and have the most changes.
The present study evaluated the levels of various cytokines in AML using flow cytometry for diagnostic purposes. Flow cytometric immunophenotypic analysis was conducted on all patients. The expression levels of CD99, CD33, CD45, CD13, HLA-DR, CD64, CD11c, and CD117 ranged from 54.58% to 90.56% in all cases. Meanwhile, MPO, CD38, CD36, CD15, CD34, CD11b, and CD2 exhibited expression levels between 24.48% and 45.06%, with the remaining CD markers showing expression levels below 20% in all cases. These findings were consistent with previous studies on AML (Rasheed et al., 2021, Piero et al., 2022). Previous researchers noted that markers such as MPO, CD13, CD33, CD15, and CD117 are specific to myeloid cells, while CD11c, CD64, CD14, and CD36 indicate monocytic lineage. Additionally, markers like CD19, CD22, CD10, CD79a, and CD20 are associated with B-lymphoid cells, while CD1a, CD2, CD3, CD4, CD5, CD7, and CD56 are linked to T-lymphoid/natural killer cells. Moreover, CD34, CD45, CD99, HLA-DR, Terminal deoxynucleotidyl transferase (TdT), and CD38 are commonly used as progenitor markers for diagnosing and classifying AML (Weir and Borowitz, 2001, Peters and Ansari, 2011).
Haematopoiesis is a highly regulated process controlled by complex molecular events that concurrently regulate hematopoietic stem cells commitment, differentiation, proliferation, and apoptosis. Substantial evidence now exists to demonstrate that microRNAs modulate haematopoiesis at the level of proliferation and differentiation and act as regulators of hematopoietic cell activity41. Differential expression of microRNAs in malignant cells compared to normal cells can be justified by their gene placement in cancer-related genomic regions, epigenetic mechanisms, and alterations in their processing mechanisms42,43. It has been established that variable expression of microRNAs plays a crucial role in leukemogenesis, and each cytogenetic alteration in AML is associated with the expression of a specific microRNA9,44. Generally, MicroRNA16 is a tumour suppressor that inhibits cell proliferation and induces apoptosis45. MicroRNA21 regulates immune responses in the body46, while MicroRNA125a, MicroRNA125b, and MicroRNA155 regulate hematopoietic stem cell activity8. MicroRNA192 plays a role in cell cycle arrest47, whereas MicroRNA221 induces cellular apoptosis48 and MicroRNA15a reduces apoptosis49. MicroRNA497 regulates cell proliferation50. In this study, the expression levels of these microRNAs were reported, and it was determined that they significantly impact disease progression. The increased expression levels of these microRNAs in AML patients are consistent with the findings of other studies that have reported higher expression of these microRNAs51,52. However, we presented for the first time the expression levels of microRNA and its correlation with CD markers in AML patients who were COVID-19 positive.
Considering that the expression patterns and levels of microRNAs can be used in disease prognosis and therapeutic responses23, the observed differences in the expression levels of microRNAs between AML patients and healthy individuals in this study are consistent with the results of other studies that have reported significant changes in the expression of microRNAs in various patients28,53. The decreased expression of microRNAs in the presence of CD markers and the concurrent decrease in CD marker expression in the presence of other CD markers align with the findings of studies by Shahrabi et al.11 and Gbarowska et al.54.
In a systematic review by Reyes-Long et al. (2023), they have demonstrated that microRNA expression levels differ between COVID-19 positive and negative patients, and these differences may be associated with the upregulation or downregulation of specific microRNAs55. Additionally, in the study by Shi et al. (2022), differences in microRNA expression among patients are observed56. The present study also found that the expression levels of microRNAs differed between COVID-19 positive and negative patients, and some microRNAs exhibited increased expression. The upregulation of microRNAs may not only be attributed to COVID-19 infection or vice versa but potentially due to the host's immune response to the virus57. Furthermore, considering the distinct expression levels of microRNAs in COVID-19 positive and negative patients, these changes in the expression levels of microRNAs could serve as suitable biomarkers58,59.
Identifying new types of microRNAs can be highly valuable and informative in understanding the mechanisms underlying various diseases, guiding therapeutic interventions, and promoting overall health improvement60,61. In the present study, microRNA 137 was identified as a novel biomarker involved in AML progression. MicroRNA137 plays a vital role in the evolution of the nervous system, the development of schizophrenia, and the maintenance of cellular homeostasis62,63. The present study showed an increased expression of MicroRNA137 in AML patients, while its expression was reduced in individuals who tested positive for COVID-19. However, a study by Wang et al. (2020) aimed to investigate the interaction between TRIM25 and MicroRNA137 and uncover their potential mechanisms in the progression of malignant AML. In that study, it was shown that there was a significant reduction in MicroRNA137 in blood samples of AML patients3. Cellular functional assays confirmed that the loss of MicroRNA137 substantially enhanced the invasion, migration, and proliferation abilities of AML cells. At the same time, overexpression of MicroRNA137 hindered the invasion, migration, and proliferation of AML cells. These findings indicated the tumour-suppressive role of MicroRNA137 in AML. However, further research is necessary due to the novelty of this microRNA. The precise significance and therapeutic target potential of MicroRNA137 may change as more is discovered about the molecular mechanisms behind AML and the involvement of microRNAs. Notably, research on MicroRNA137 and its role in AML is still underway. Targeting MicroRNA137in AML treatment may offer further therapeutic benefits, which will be further explored in subsequent research and clinical trials.
The present study demonstrated an increase in fold changes and microRNA expression in individuals who tested positive for COVID-19, and this increase was observed across all examined microRNAs. These findings are consistent with the results of studies conducted by Donyavi et al.59, Farr et al.64, and Li et al.65. This observation led us to understand that increased correlations for the expressions of genes in the cancer networks associated with decreased correlations for the expressions of genes in the standard networks might serve as valid biomarkers for early diagnosis of tumorigenesis and cancer progression. Finally, the identification of different MicroRNAs, the discovery of their target sequences, and the investigation of their gene expression pattern change in various cancers, including AML, along with their association with different cytogenetic abnormalities in AML patients, can provide a basis for more precise disease investigations, drug design, and the development of novel treatments for various types of cancer, including AML.
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Recently, scientists found that some people who suffered from COVID-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signaling proteins. Now, researchers conducted an in-depth study on 123 Japanese COVID-19 patients to clarify just how common these auto-antibodies are among severe cases and how they affect the immune system. Their findings could shed light on the role of auto-antibodies in exacerbating COVID-19 severity.
Even though COVID-19 manifests as a mild and short-lived disease in most people, some suffer extremely severe symptoms; in the worst cases, these patients die due to complications such as respiratory failure or thromboembolism. It is well-known that factors such as age and underlying medical conditions like diabetes or immunodeficiencies increase vulnerability to severe COVID-19. However, some patients still experience severe COVID-19 without any apparent reason.
One possible explanation may lie in auto-antibodies, which are antibodies that erroneously target specific proteins produced by ones own body. In normal circumstances, type I interferons (or t1-IFNs) play a crucial role in the bodys defense against viral infections; they interfere with viral replication and help mobilize the immune system. However, auto-antibodies against t1-IFNs can neutralize their activity, compromising the bodys defense mechanisms. While detecting these auto-antibodies was uncommon before COVID-19, there have been multiple reports of severe COVID-19 patients bearing them since the pandemic started. Could auto-antibodies targeting t1-IFNs be more common than previously thought?
To answer this question, a research team, including Lecturer Chiaki Iwamura from Chiba University, Japan, investigated whether and how auto-antibodies targeting t1-IFNs are related to COVID-19 severity by analyzing blood samples from 123 Japanese patients. Their findings were published in Volume 44 of theJournal of Clinical Immunologyon April 22, 2024. This research was co-authored by Dr. Kiyoshi Hirahara and Dr. Koutaro Yokote from Chiba University, as well as Dr. Ami Aoki from Niigata University.
Subscribe to Technology Networks daily newsletter, delivering breaking science news straight to your inbox every day.
To shed some light on how auto-antibodies to t1-IFNs affected COVID-19 patients, the researchers then conducted RNA sequencing and B cell receptor analyses. These experiments showed that conventional dendritic cells and canonical monocytes, two types of white blood cells, exhibited attenuated IFN signaling for patients in which auto-antibodies were present. Moreover, B cells (yet another type of immune cell) in these patients had fewer SARS-CoV-2-specific receptors, implying reduced effectiveness in combating an infection.
Overall, these findings highlight the importance of looking at auto-antibodies to t1-IFNs in more detail when facing viral epidemics. People with auto-antibodies to t1-IFNs are more susceptible not only to SARS-CoV-2 but also to common viruses such as influenza and to unknown viruses that may emerge in the future, warns Dr. Iwamura, Thus, we hope to collaborate with companies to develop a system to detect auto-antibodies to t1-IFNs in the blood. Ideally, we would develop a test to examine the presence of these auto-antibodies in regular health checkups so that people will be able to know whether they have them with little burden.
Reference:Aoki A, Iwamura C, Kiuchi M, et al. Suppression of type I interferon signaling in myeloid cells by autoantibodies in severe COVID-19 patients. J Clin Immunol. 2024;44(4):104. doi: 10.1007/s10875-024-01708-7
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
